4
|
Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM. Recommendations for Clinical Trial Development in Follicular Lymphoma. J Natl Cancer Inst 2016; 109:2758474. [PMID: 28040699 DOI: 10.1093/jnci/djw255] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Revised: 06/24/2016] [Accepted: 09/27/2016] [Indexed: 12/18/2022] Open
Abstract
Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.
Collapse
Affiliation(s)
- Kami Maddocks
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Paul M Barr
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Bruce D Cheson
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Richard F Little
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Lawrence Baizer
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Brad S Kahl
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - John P Leonard
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Nathan Fowler
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Leo I Gordon
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Brian K Link
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Jonathan W Friedberg
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| | - Stephen M Ansell
- Affiliations of authors: The Ohio State University, Columbus, OH (KM); University of Rochester Medical Center, Rochester, NY (PMB); Georgetown University Hospital, Washington, DC (BDC); Division of Cancer Treatment and Diagnosis (RFL) and Coordinating Center for Clinical Trials (LB), National Cancer Institute, Bethesda, MD; Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Medicine, Weil Cornell University, New York, NY (JPL); The University of Texas MD Anderson Cancer Center, Houston, TX (NF); Northwestern University, Chicago, IL (LIG); University of Iowa, Iowa City, IA (BKL); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Mayo Clinic, Rochester, MN (SMA)
| |
Collapse
|
8
|
Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 2016; 27:895-901. [PMID: 26802151 DOI: 10.1093/annonc/mdw026] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2015] [Accepted: 01/12/2016] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND The optimal initial therapy of follicular lymphoma (FL) remains unclear. The aims of this study were to compare primary treatment strategies and assess the impact of maintenance rituximab and patterns of treatment failure. PATIENTS AND METHODS We retrospectively analyzed patients with treatment-naive advanced stage, grade 1-2 FL treated at our center from 2004 to 2014. We included 356 patients treated on clinical trials or standard of care with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP, n = 119); R-CHOP with maintenance (R-CHOP + M, n = 65); bendamustine/rituximab (BR, n = 45); BR with maintenance (BR + M, n = 35); R(2) (n = 94). We compared baseline characteristics, progression-free survival (PFS), overall survival (OS) and analyzed prognostic factors using univariate and multivariate analysis adjusted for treatment. RESULTS After a median follow-up of 4 years (range 0.2-15.0), the 3-year PFS was 60% [95% confidence interval (CI) 51% to 69%] for R-CHOP, 72% (59% to 82%) for R-CHOP + M, 63% (42% to 78%) for BR, 97% (80% to 100%) for BR + M and 87% (78% to 93%) for R(2). Patients treated with R-chemotherapy had more high-risk features than patients treated with R(2) but, by adjusted multivariate analysis, treatment with R(2) [hazard ratio (HR) 0.39 (0.17-0.89), P = 0.02] was associated with a superior PFS. Eastern Cooperative Oncology Group Performance status of one or more predicted inferior OS. Among patients treated with R-chemotherapy, maintenance was associated with the superior PFS [HR 0.38 (95% CI 0.21-0.68)]. By adjusted multivariate analysis, disease progression within 2 years [HR 5.1 (95% CI 1.57-16.83)] and histologic transformation (HT) [HR 11.05 (95% CI 2.84-42.93)] increased risk of death. CONCLUSION Induction therapy with R(2) may result in disease control which is comparable with R-chemotherapy. Early disease progression and HT are predictive of inferior survival.
Collapse
Affiliation(s)
- C Y Cheah
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA Department of Haematology, Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Perth School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia
| | - D Chihara
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - M Ahmed
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - R E Davis
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - L J Nastoupil
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - K Phansalkar
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - F B Hagemeister
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - L E Fayad
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - J R Westin
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - Y Oki
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - M A Fanale
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - J E Romaguera
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - M L Wang
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - H Lee
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - F Turturro
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - F Samaniego
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - M A Rodriguez
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - S S Neelapu
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| | - N H Fowler
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA
| |
Collapse
|